Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review
Open Access
- 28 November 2019
- journal article
- review article
- Published by Elsevier BV in Annals of Hepatology
- Vol. 19 (3), 232-237
- https://doi.org/10.1016/j.aohep.2019.10.005
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Lower Risk of Cancer in Patients on Metformin in Comparison With Those on Sulfonylurea DerivativesDiabetes Care, 2011
- Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver diseaseLiver International, 2010
- Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinomaCancer, 2010
- AMPK as a metabolic tumor suppressor: control of metabolism and cell growthFuture Oncology, 2010
- Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: Potential role of insulinWorld Journal of Gastroenterology, 2008
- The Role of Obesity and Related Metabolic Disturbances in Cancers of the Colon, Prostate, and PancreasGastroenterology, 2007
- Long-Term Efficacy of Metformin Therapy in Nonobese Individuals With Type 2 DiabetesDiabetes Care, 2006
- The Association Between Diabetes and Hepatocellular Carcinoma: A Systematic Review of Epidemiologic EvidenceClinical Gastroenterology and Hepatology, 2006
- AMP‐activated protein kinase: role in metabolism and therapeutic implicationsDiabetes, Obesity and Metabolism, 2006
- The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetesDiabetic Medicine, 2005